# US 2024/0201193 A1 · Method for treating cancer using immune checkpoint inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201193 A1
- Document ID: US20240201193A1
- Status: Published application
- Kind: A1
- Application number: 18/554,629
- Filed: 2022-04-08
- Published: 2024-06-20
- Earliest claimed: 2021-04-09
- Applicants: Cytogen, Inc.
- Inventors: Byung Hee JEON
- Web page: https://patentgrep.com/patent/US20240201193A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- G01N 33/5752: of the lungs
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/582: {with fluorescent label}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a method for treating cancer using an immune checkpoint inhibitor, and more particularly, to a method for treating cancer by identifying the expression of an immune checkpoint protein and a lymphoid or myeloid cell-specific protein in circulating tumor cells isolated from blood, sorting patients, in whom the expression of the immune checkpoint protein and the expression of the lymphoid or myeloid cell-specific protein are identified as positive, as patients to whom an immunotherapeutic anticancer agent can be applied, and administering the immune checkpoint inhibitor to the patients. Since the method for treating cancer using circulating tumor cells according to the present invention sorts patients by simultaneously identifying the expression of an immune checkpoint protein and a lymphoid or myeloid cell-specific protein in a liquid biopsy, the method has a very high level of agreement with biopsies, and thus a high degree of commercial utility. Therefore, the method according to the present invention is useful for diagnosing and treating cancer.

## Claims

### Claim 1

A method of selecting a patient for application of cancer immunotherapy drug, comprising:
(a) confirming expression of an immune checkpoint protein and a lymphoid or myeloid-specific protein in circulating tumor cells; and
(b) classifying a patient in whom immune checkpoint protein expression is confirmed as positive and lymphoid or myeloid-specific protein expression is confirmed as positive as a patient to whom cancer immunotherapy drug is applicable.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the immune checkpoint protein is selected from the group consisting of PD-1, PD-L1, and CTLA-4.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the lymphoid or myeloid-specific protein is selected from the group consisting of CD18, CD16, CD29, CD61, CD104, CD32, CD11b, and CD64.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the circulating tumor cells are isolated by:
(i) obtaining blood from a cancer patient; and
(ii) isolating circulating tumor cells from the blood using a biochip.

### Claim 5 (depends on 1)

The method according to claim 1, wherein confirming the expression of the immune checkpoint protein and the lymphoid or myeloid-specific protein is performed by:
(1) carrying out reaction with a fluorescent marker that specifically binds to circulating tumor cells, a fluorescent marker that specifically binds to an immune checkpoint protein, and a fluorescent marker that specifically binds to a lymphoid or myeloid-specific protein;
(2) receiving optical images in multiple wavelength ranges for the circulating tumor cells, the immune checkpoint protein, and the lymphoid or myeloid-specific protein, reacted with the fluorescent markers;
(3) performing primary filtering by measuring fluorescence intensities of the circulating tumor cells, the immune checkpoint protein, and the lymphoid or myeloid-specific protein in optical images of all or part of the multiple wavelength ranges;
(4) performing secondary filtering by measuring morphology of the circulating tumor cells in the optical images of all or part of the multiple wavelength ranges; and
(5) performing tertiary filtering by measuring morphology of the circulating tumor cells in an integrated image obtained by merging all or part of the optical images in the multiple wavelength ranges.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the fluorescent marker that specifically binds to the circulating tumor cells is selected from the group consisting of a vimentin-specific antibody, an EpCAM-specific antibody, and a CK-specific antibody.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the fluorescent marker that specifically binds to the immune checkpoint protein is selected from the group consisting of a PD-1-specific antibody, a PD-L1-specific antibody, and a CTLA-4-specific antibody.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the fluorescent marker that specifically binds to the lymphoid or myeloid protein is selected from the group consisting of a CD18-specific antibody, a CD16-specific antibody, a CD29-specific antibody, a CD61-specific antibody, a CD104-specific antibody, a CD32-specific antibody, a CD11b-specific antibody, and a CD64-specific antibody.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the cancer immunotherapy drug is an antibody.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the cancer immunotherapy drug is a monoclonal antibody.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the cancer immunotherapy drug is a human antibody, a humanized antibody, or a chimeric antibody.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the cancer immunotherapy drug is at least one selected from the group consisting of a PD-L1 antagonist, a PD-1 antagonist, and a CTLA-4 antagonist.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the cancer immunotherapy drug is at least one selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Lybtayo), atezolizumab (Tecentriq), avelumab (Bacencio), durvalumab (Imfinzi), ipilimumab (Yervoy), and tremelimumab.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the cancer is selected from the group consisting of lung cancer, kidney cancer, bladder cancer, breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, gastric carcinoma, esophageal cancer, mesothelioma, melanoma, head and neck cancer, thyroid cancer, sarcoma, prostate cancer, glioblastoma, cervical cancer, thymic carcinoma, leukemia, lymphoma, myeloma, mycosis fungoides, Merkel cell cancer, and hematological malignancies.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the cancer is lung cancer.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the cancer is non-small cell lung cancer.

### Claim 17

A method of selecting cancer immunotherapy for a cancer patient, comprising:
(a) confirming expression of an immune checkpoint protein and a lymphoid or myeloid-specific protein in isolated circulating tumor cells (CTCs); and
(b) selecting an immune checkpoint inhibitor as therapy when immune checkpoint protein expression is positive and lymphoid or myeloid-specific protein expression is positive.

### Claim 18

A method of treating cancer, comprising:
(a) confirming expression of an immune checkpoint protein and a lymphoid or myeloid-specific protein in circulating tumor cells; and
(b) administering an immune checkpoint inhibitor when immune checkpoint protein expression is positive and lymphoid or myeloid-specific protein expression is positive.

### Claim 19

A method of determining susceptibility to an immune checkpoint inhibitor, comprising:
(a) confirming expression of an immune checkpoint protein and a lymphoid or myeloid-specific protein in circulating tumor cells; and
(b) determining that there is susceptibility to an immune checkpoint inhibitor when immune checkpoint protein expression is positive and lymphoid or myeloid-specific protein expression is positive.
